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Abstract 
Review on der(1;9)(q10;p10), with data on clinics. 
Clinics and pathology 
Disease 
Myeloid malignancies, rarely acute lymphocytic 
leukemia (ALL), multiple myeloma (MM) and 
lymphoma. 
Phenotype/cell stem origin 
10 patients were diagnosed with myeloid 
malignacies: polycythemia vera (PV) 7 cases (den 
Nijs van Weert et al., 1989;  Swolin et al., 1986; 
Rege-Cambrin et al., 1991; Boiocchi et al., 2013), 
myelofibrosis (MF) 2 (Rege-Cambrin et al., 1991; 
Reilly et al., 1997) and acute myeloid leukemia 1 
patient (Bobadilla et al., 2007). There were 4 
multiple myeloma  MM (Mohamed et al., 2007; 
Gabrea et al., 2008; Sawyer et al., 2014), 1 ALL 
(Uckun et al., 1998) and 1 diffuse large B-cell 
lymphoma (Martin-Subero et al., 2007) cases (Table 
1). 
Epidemiology 
Rare anomaly, found in 6 male and 10 female 
patients aged 30 to 62 years. 
Prognosis 
Found in association with leukaemic or 
myelofibrotic transformation in 7 out of 10 myeloid 
cases; may represent a poor  prognostic indicator 




Presents as 2 normal chromosomes 1, one normal 
chromosome 9 and a der(9)t(1;9) chromosome in 4 
patients and as +der(1;9)(q10;p10) in 12 cases. 
Additional anomalies 
Found as the sole abnormality in 1 patient (den Nijs 
van Weert et al., 1989) and most frequently in 
combination with numerical anomalies in myeloid 
cases: loss of chromosomes 5 (Swolin et al., 1986) 
and/or 7 (Swolin et al., 1986; den Nijs van Weert et 
al., 1989) in 2 and with extra chromosome 8 in 4 
patients (Swolin et al 1986; den Nijs van Weert et 
al., 1989; Rege-Cambrin et al., 1991).  
Numerical gain of chromosome 9, detected in 4 
patients (Swolin et al 1986; den Nijs van Weert et 
al., 1989; Boiocchi et al 2013) is of special interest 
since it was found only in independent clones that 
appeared simultaneously or in sequence  including 
the case presenting with trisomy 9 as a sole anomaly 
who developed an extra der(1;9) during the course of 
the disease with disapperance of the extra 
chromosome 9 (den Nijs van Weert et al., 1989).  
A t(1;9)(p10;q10) in addition to der(1;9)(q10;p10) 
chromosome was observed in two patients (Swolin 
et al., 1986; Reilly et al., 1997).  
Deletions of the long arms of either chromosome 13 
(Rege-Cambrin et al., 1991) or20 (Swolin et al., 
1986) appeared in 3 patients and 2 reported patients 
showed 12p rearrangements (den Nijs van Weert et 
al., 1989; Bobadilla et al., 2007). 















Disease Karyotype  
      Myeloid disorders 
















46,XX,-5,del(20)(q11),+mar/46,idem,+der(1;9)(q10;p10),+7   
45-46,XX,-5,-7,del(20),+1-2mar  
6. M/60 Post MF AML  
47,XY,+der(1;9)(q10;p10)br />47,XY,+der(1;9),del(13)(q13q31) 
48,XY,+der(1;9),+8,del(13) 
7. F/62 Post PV AML 48,XX,+der(1;9)(q10;p10),+8,del(13)(q11q14)/51,XX,+der(1;9)x2,+8,+14,+19 
8. M/59 MF 47,XY,t(1;9)(p10;q10),+der(1;9)(q10;p10)  
9. M/37 AML-M0 46,XY,t(3;12)(q26;p13)/46,idem,der(1;9)(q10;p10) 
10. M Post PV MF 47,XY,+der(1;9)(q10;p10)/47,XY,+9 
      Other malignancies 
11. F ALL 
46,XX,+1,der(1;9)(q10;p10),i(7)(q10),der(19)t(1;19)(q23;p13)/48,XX,+5,i(7)(q10
),+8,der(19)t(1;19)(q23;p13)   





13.  F/43 MM 48-49,X,-X,der(1;9)(q10;p10),t(1;8)(p21;q24),+3,add(5)(q35),-16,+18,+19,+21   




(q10)x3,+add(9)(p21)x2,add(12)(p12),-13,+add(15)(q26)x2,+21,+del(22)(q13)   




del(13)(q13q14),+15,add(16)(q24),+19,+21,+22,+mar   




del(10)(q11),-13,+19,+mar/93-101,idemx2,-add(X),der(14)t(1;14)(q?21;p11),inc   
Table 1. Reported patients with der(1;9)(q10;p10). Abbreviations: PV., polycythemia vera;  AML-M4., acute  myelomonocytic 
leukemia; MF.,  myelofibrosis., AML-M0., acute myeloblastic leukemia with minimal  differentiation; AML-M6., acute  
erythroleukemia; ALL., acute lymphoblastic leukemia; DLBCL., diffuse large B-cell lymphoma; LN., lymph node; MM., multiple 
myeloma.  
1-2. den Nijs  van Weert et al., 1989; 3-5. Swolin et al., 1986; 6-7. Rege-Cambrin et al.,  1991; 8. Reilly et al., 1997; 9. Bobadilla 
et al., 2007; 10. Boiocchi et al  2013; 11. Uckun et al., 1998; 12. Martin-Subero et al., 2007; 13. Mohamed et al., 2007; 14-15. 
Gabrea et al., 2008; 16. Sawyer et al.,  2014. 
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Acquired whole-arm chromosome translocations 
(WAT) of the long arm of chromosome 1 are 
nonrandom in hematologic malignancies and 
commonly involve centromeric or paracentromeric 
sites of chromosome partners. Mostly, these 
rearrangements are unbalanced leading to genomic 
imbalances, such as 1q trisomy and monosomy of 
the whole-arm of the involved chromosome. The 
unbalanced der(1;9)(q10;p10) is created by 
translocation between the whole arms of 
chromosomes 1 and 9 by fusion in their centromeric 
regions probably as a result of heterochromatin 
breakage and reunion in centromeric sequences 
(Sambani et al., 2005). Structural homologies of 
large blocks of constitutive heterochromatin in 
chromosome 1 and 9 centromeric regions might 
favor such recombination.  
der(1;9)(q10;p10) is a relatively rare cytogenetic 
aberration that presumably occur in 
myeloproliferative neoplasms (den Nijs van Weert et 
al., 1989; Rege-Cambrin et al., 1991). In the majority 
of these cases, it was found as +der(1;9)(q10;p10), 
therefore leading to trisomy of both 1q and 9p arms. 
The formation of an extra copies of the entire 
chromosome arms are likely to be  implicated in a 
neoplastic processes by a gene dosage effect, 
analogous to numerical aberrations.  
The occurrence of +9 in patients with 
myeloproliferative disorders is of special interest 
with respect to the JAK2 gene on 9p24.1, suggesting 
that JAK2 copy number may play a pathogenetic 
role.  
This is supported by observation of a series of MPNs 
patients with t(1;9) describing that patients with 
either trisomy 9/+9p are invariably JAK2V617F-
positive. The majority of these cases also possessed 
amplification of the gene in addition to the mutation, 
thus JAK2 activating mutations may cooperate with 
9/9p trisomy. It can be hypothesized that the gain-of-
function of JAK2 contributes to the disease 
phenotype while its enhanced constitutive activation 
provides a proliferative advantage (Reilly et al., 
2008; Campbell et al., 2006). While the timing of the 
JAK2 mutation is unclear, the occurrence of 
common trisomies and non-random chromosome 
deletions in these patients suggests that it may not be 
the initiating event, but chromosome aneuploidy and 
gene deletions may precede the acquisition of JAK2 
mutations. These data suggest that multiple genetic 
events may be associated with the development of 
der(1;9)(q10;p10) that frequently coexists at 
presentation or later during the further course of the 
disease. The der(1;9)(q10;p10) is usually present 
with additional common abnormalities, therefore it 
is likely to be a secondary event, representing clonal 
evolution that may play a role in disease progression. 
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